A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Alexandra S ZimmerErin NicholsAshley Cimino-MathewsCody PeerLiang CaoMin-Jung LeeElise C KohnChristina M AnnunziataStanley LipkowitzJane B TrepelRajni SharmaLekha MikkilineniMargaret Gatti-MaysWilliam D FiggNicole D HoustonJung-Min Lee

Published in: Journal for immunotherapy of cancer (2019)

ClinicalTrials.gov identifier: NCT02484404. Registered June 29, 2015.

Keyphrases

polycystic ovary syndrome
dna damage
type diabetes
dna repair
vascular endothelial growth factor
pregnant women
adipose tissue
oxidative stress
pregnancy outcomes
skeletal muscle
endothelial cells